A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult
A phase 2 trial of Telisotuzumab vedotin in non-small-cell lung cancer and small-cell lung cancer, run by AbbVie, now recruiting.
Overview
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) is a phase 2 interventional study registered as NCT06568939 by AbbVie, with 150 participants planned, started 2025-01-20 and due to reach its primary completion in 2028-02. Interventions recorded: Telisotuzumab Vedotin. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialLUMINOSITY
- TrialTeliMET NSCLC-01
- TrialA Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Shares AbbVie (incl. ImmunoGen, Capstan), Non-small-cell lung cancer.
- TrialA Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Shares AbbVie (incl. ImmunoGen, Capstan), Non-small-cell lung cancer.
- TrialStudy to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Shares AbbVie (incl. ImmunoGen, Capstan), Non-small-cell lung cancer.
- TrialA Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
Shares AbbVie (incl. ImmunoGen, Capstan), Non-small-cell lung cancer.
- TreatmentABBV-706
Shares AbbVie (incl. ImmunoGen, Capstan), Non-small-cell lung cancer.
- TermMET amplification (bypass resistance)